W. Eiermann

44.2k total citations · 7 hit papers
224 papers, 23.7k citations indexed

About

W. Eiermann is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, W. Eiermann has authored 224 papers receiving a total of 23.7k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Oncology, 108 papers in Cancer Research and 57 papers in Genetics. Recurrent topics in W. Eiermann's work include Breast Cancer Treatment Studies (96 papers), HER2/EGFR in Cancer Research (63 papers) and Cancer Treatment and Pharmacology (58 papers). W. Eiermann is often cited by papers focused on Breast Cancer Treatment Studies (96 papers), HER2/EGFR in Cancer Research (63 papers) and Cancer Treatment and Pharmacology (58 papers). W. Eiermann collaborates with scholars based in Germany, United States and Spain. W. Eiermann's co-authors include José Baselga, Janet Wolter, Dennis J. Slamon, Mark D. Pegram, Virginia Paton, Alex Bajamonde, Steven Shak, Brian Leyland‐Jones, Thomas Fleming and Larry Norton and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

W. Eiermann

214 papers receiving 23.1k citations

Hit Papers

Use of Chemotherapy plus a Monoclonal Antibody against HE... 2001 2026 2009 2017 2001 2012 2018 2010 2006 2.5k 5.0k 7.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
    2001 8.4k citations Dennis J. Slamon, W. Eiermann et al. New England Journal of Medicine profile →
  2. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
    2012 1.8k citations Gϋnter von Minckwitz, Michael Untch et al. Journal of Clinical Oncology profile →
  3. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
    2018 1.4k citations Jennifer K. Litton, Hope S. Rugo et al. New England Journal of Medicine profile →
  4. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
    2010 891 citations Luca Gianni, W. Eiermann et al. profile →
  5. Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update
    2006 548 citations Manfred Kaufmann, Jens‐Uwe Blohmer et al. Journal of Clinical Oncology profile →
  6. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
    2001 530 citations W. Eiermann, Stefan Paepke et al. Annals of Oncology profile →
  7. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
    2020 252 citations Jennifer K. Litton, Sara A. Hurvitz et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W. Eiermann Germany 52 16.4k 10.0k 5.8k 4.9k 4.6k 224 23.7k
Steven Shak United States 54 16.7k 1.0× 11.2k 1.1× 6.0k 1.0× 8.1k 1.6× 5.6k 1.2× 133 28.1k
Sandra M. Swain United States 66 15.4k 0.9× 7.2k 0.7× 4.9k 0.8× 5.1k 1.0× 4.8k 1.1× 337 23.4k
Michael Untch Germany 65 12.6k 0.8× 10.1k 1.0× 3.9k 0.7× 3.7k 0.7× 3.7k 0.8× 542 19.7k
Gϋnter von Minckwitz Germany 78 16.4k 1.0× 13.2k 1.3× 4.1k 0.7× 4.2k 0.9× 3.9k 0.9× 428 25.0k
Ana M. González-Angulo United States 83 15.2k 0.9× 11.4k 1.1× 2.7k 0.5× 8.9k 1.8× 5.2k 1.1× 281 25.2k
Louis Fehrenbacher United States 63 25.3k 1.5× 8.0k 0.8× 4.5k 0.8× 8.9k 1.8× 10.2k 2.2× 157 35.9k
Charles E. Geyer United States 49 11.3k 0.7× 8.6k 0.9× 3.1k 0.5× 2.5k 0.5× 3.2k 0.7× 183 16.3k
Brian Leyland‐Jones United States 53 11.6k 0.7× 4.6k 0.5× 4.1k 0.7× 5.7k 1.2× 3.3k 0.7× 218 18.4k
Sibylle Loibl Germany 76 19.6k 1.2× 13.4k 1.3× 3.4k 0.6× 6.1k 1.2× 8.4k 1.8× 588 29.5k
Mark D. Pegram United States 56 17.8k 1.1× 4.9k 0.5× 8.5k 1.5× 6.8k 1.4× 4.6k 1.0× 221 23.8k

Countries citing papers authored by W. Eiermann

Since Specialization
Citations

This map shows the geographic impact of W. Eiermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Eiermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Eiermann more than expected).

Fields of papers citing papers by W. Eiermann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Eiermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Eiermann. The network helps show where W. Eiermann may publish in the future.

Co-authorship network of co-authors of W. Eiermann

This figure shows the co-authorship network connecting the top 25 collaborators of W. Eiermann. A scholar is included among the top collaborators of W. Eiermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Eiermann. W. Eiermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Litton, Jennifer K., Sara A. Hurvitz, Lida A. Mina, et al.. (2020). Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Annals of Oncology. 31(11). 1526–1535. 252 indexed citations breakdown →
2.
3.
Litton, Jennifer K., HS Rugo, Johannes Ettl, et al.. (2018). Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation. Cancer Research. 78(4_Supplement). GS6–7. 40 indexed citations
4.
Press, Michael F., José A. Seoane, Christina Curtis, et al.. (2018). Assessment ofERBB2/HER2Status inHER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines. JAMA Oncology. 5(3). 366–366. 25 indexed citations
5.
Litton, Jennifer K., Hope S. Rugo, Johannes Ettl, et al.. (2018). Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. New England Journal of Medicine. 379(8). 753–763. 1401 indexed citations breakdown →
6.
7.
Stern, Howard M., Humphrey Gardner, Tomasz Burzykowski, et al.. (2015). PTEN Loss Is Associated with Worse Outcome in HER2 -Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. Clinical Cancer Research. 21(9). 2065–2074. 57 indexed citations
8.
Denkert, Carsten, Sibylle Loibl, Berit Müller, et al.. (2013). Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Annals of Oncology. 24(11). 2786–2793. 172 indexed citations
9.
Minckwitz, Gϋnter von, Jens‐Uwe Blohmer, Serban Dan Costa, et al.. (2013). Response-Guided Neoadjuvant Chemotherapy for Breast Cancer. Journal of Clinical Oncology. 31(29). 3623–3630. 265 indexed citations
10.
Ataseven, Beyhan, Ronald Kates, Pjotr Knyazev, et al.. (2013). PTK7 expression in triple-negative breast cancer.. PubMed. 33(9). 3759–63. 32 indexed citations
11.
Eiermann, W. & Katherine A. Vallis. (2012). Locoregional treatments for triple-negative breast cancer. Annals of Oncology. 23. vi30–vi34. 20 indexed citations
12.
Meyer, Peter, et al.. (2012). BRCA2 Mutations and Triple-Negative Breast Cancer. PLoS ONE. 7(5). e38361–e38361. 28 indexed citations
13.
Kaiser, Claudia, et al.. (2011). Vaginale Hysterektomie und beidseitige Adnexektomie in interdisziplinärem Konzept bei Frau zu Mann – Transsexualismus. Handchirurgie · Mikrochirurgie · Plastische Chirurgie. 43(4). 240–245. 13 indexed citations
14.
Bianchi, Giulia, W. Eiermann, Giordano Vitali, et al.. (2003). Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.. PubMed. 9(16 Pt 1). 5944–51. 41 indexed citations
15.
Raab, G. & W. Eiermann. (2001). Trastuzumab, ein neuer Behandlungsansatz beim Mammakarzinom. Der Internist. 42(6). 835–842. 1 indexed citations
16.
Jonat, W., Anthony Howell, Carl Blomqvist, et al.. (1996). A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *. European Journal of Cancer. 32(3). 404–412. 207 indexed citations
17.
Meier, Werner, P Stieber, W. Eiermann, et al.. (1989). Serum levels of CA 125 and histological findings at second-look laparotomy in ovarian carcinoma. Gynecologic Oncology. 35(1). 44–46. 6 indexed citations
18.
Beck, Rainer, S. Heywang, W. Eiermann, W Permanetter, & J. Lissner. (1987). [Contrast enhancement of the nipple in nuclear magnetic resonance tomography of the breast with Gd-DTPA].. PubMed. 7(4). 167–9. 2 indexed citations
19.
Heywang, S., et al.. (1985). Carcinoma of the breast behind a prosthesis—Comparison of ultrasound, mammography and MRI (case report). Computerized Radiology. 9(5). 283–286. 6 indexed citations
20.
Eiermann, W., et al.. (1979). [Correlation between ectopic production of beta1-glycoprotein and human placental lactogen and prognosis of breast cancer].. PubMed. 228(1-4). 659–659. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven Shak Breakdown of academic impact, for papers by Sandra M. Swain Breakdown of academic impact, for papers by Michael Untch Breakdown of academic impact, for papers by Gϋnter von Minckwitz Breakdown of academic impact, for papers by Ana M. González-Angulo Breakdown of academic impact, for papers by Louis Fehrenbacher Breakdown of academic impact, for papers by Charles E. Geyer Breakdown of academic impact, for papers by Brian Leyland‐Jones Breakdown of academic impact, for papers by Sibylle Loibl Breakdown of academic impact, for papers by Mark D. Pegram
Rankless by CCL
2026